



Prescribing Basal-Bolus Made Easy

All commercially insured patients have access to V-Go and V-Go is covered on Medicare Part D

How to Prescribe

Send Prescriptions to Patients' Preferred Pharmacy

1

Select the appropriate V-Go Dose Option



Example Prescription For:
V-Go Device

Rx: V-Go 20, 30 or 40

Dispense: #1 box of 30 V-Go devices for 30 days

Sig: Use 1 V-Go every 24 hours as directed

SIGNATURE _____ DATE _____



2

V-Go is filled with a U-100 Rapid-Acting Insulin



Example Prescription For:
Insulin to Fill V-Go 30

Rx: U-100 rapid-acting insulin

Dispense: #3 x 10 mL vials

Sig: Administer up to _____ U/day

**Per FDA Labeling
Required Vials/Month:**

#2 x 10 mL vials required for V-Go 20
#3 x 10 mL vials required for V-Go 30
#3 x 10 mL vials required for V-Go 40



The majority of V-Go prescriptions are filled by simply sending the prescription to the patients' preferred pharmacy.

*If V-Go is not covered by your patients' insurance plan and they are commercially insured, a cash pay option is available.

To access V-Go cash pay* for a patient e-prescribe the V-Go prescription to:

UBC Pharmacy LLC
600 Emerson Road, Suite 300
Creve Coeur, MO 63141
NPI: 1962978858
Fax: 1-866-750-9260 Phone: 1-855-822-7948

*Cash pay is only available for commercially insured patients when V-Go is not covered by their plan.


mannkind



Initiating V-Go for Basal-Bolus

V-Go provides a consistent 24-hour continuous basal infusion and on-demand bolus dosing with meals

V-Go is available in 3 dosing options¹



The Bolus Delivery Button can be clicked 18 times in every 24-hour period. 1 click= 2 units
V-Go is applied like a patch and once filled delivers a basal rate of insulin and on-demand bolus dosing.

*Individual dosing needs may vary

1. V-Go Instructions for Patient Use. DCN 2560 Rev. C 06/2022. 2. Adapted from Edelman SV, Bode BW, Bailey TS, et al. Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. 3. Chun J, Strong J, Urquhart S. Insulin Initiation and Titration in Patients With Type 2 Diabetes. Diabetes Spectr. 2019 May;32(2):104-111.

Important Safety Information: If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Wearable Insulin Delivery device may result in hypoglycemia. The following conditions may occur during insulin therapy with V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or skin infections at the infusion site. V-Go is magnetic resonance (MR) unsafe and should be removed before having an X-ray, MRI or CT scan.

V-GO, V-GO WEARABLE INSULIN DELIVERY and MANNKIND logo are registered trademarks of MannKind Corporation
US-VGO-0120 07/2023 © 2023 MannKind Corporation

V-Go Dosing Guidance in Patients Switching from MDI*^{2,3}

